The quality assurance program of the ACO Organkommission OVAR (QS-OVAR): Pattern of care and reality in Germany 2001;Das qualitätssicherungsprogramm der AGO Organkommission OVAR (QS-OVAR): Versorgungsstruktur und realität in Deutschland 2001

Zentralblatt fur Gynakologie

Volumn 127, Issue 1, 2005, Pages 9-17

  Du Bois, Andreas ^a,b,f   Rochon, J ^c   Lamparter, C ^d   Pfisterer, J ^b,e  

^a HSK Wiesbaden   (Germany)

^b AGO Organkommission OVAR ^*  (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d MMF Marktforschung GmbH Herdecke   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Guideline; Ovarian neoplasm; Pattern of care; Quality of care

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE QUALITY; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT CARE; PERITONEAL BIOPSY; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; PROGNOSIS; QUALITY CONTROL; REVIEW; SALPINGOOOPHORECTOMY;

DELIVERY OF HEALTH CARE; FEMALE; GERMANY; HEALTH SURVEYS; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; QUALITY ASSURANCE, HEALTH CARE;

EID: 14044272793     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-836289     Document Type: Review

References (26)

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland. 3. erw. Aufl., Saarbrücken 2002
2. Goodmann MT, Howe HL. Descriptive epidemiology of ovarian cancer in the United States, 1992-1997. Cancer 2003; 97 (Suppl): 2615-2630
3. Berrino F, Capocaccia R, Esteve J et al (eds). Survival of cancer patients in Europe: the EUROCARE-2 study. IARC Scientific Publications No. 151, Lyon 1999
4. Berrino F, Capocaccia R, Coleman MP et al (eds). Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003; 14 (Suppl 5): v1-v155
5. Barnholtz-Sloan JS, Schwartz AG, Qureshi F et al. Ovarian cancer: Changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003; 189: 1120-1127
6. Kumpulainen S, Grenman S, Kyyrönen P et al. Evidence of benefit from centralised treatment of ovarian cancer: A nationwide population-based survival analysis in Finland. Int J Cancer 2002; 102: 541-544
7. Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 2003 ; 102: 499-505
8. Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer 1994; 70: 352-362
9. du Bois A, Pfisterer J, Kellermann L et al. Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluss hat die Teilnahme an klinischen Studien? Geburtsh Frauenheilkd 2001; 61: 863-871
10. Bauknecht T, Breitbach GP, du Bois A et al. Maligne Ovarialtumoren. In: Deutsche Krebsgesellschaft e.V. Qualitätssicherung in der Onkologie, kurzgefasste interdisziplinäre Leitlinien 2000. Zuckschwerdt Verlag, München 2000; pp 301-318
11. Arbeitsgemeinschaft Gynäkologische Onkologie Organkommission OVAR. Ovarialkarzinom State of the Art 2003.
12. du Bois A, Pfisterer J, Kellermann L. Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Ergebnisse einer Umfrage der Organkommission OVAR der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) in der Deutschen Krebsgesellschaft. Gynäkologe 2001; 34:1029-1040
13. du Bois A, Rochon J, Lamparter C et al. Pattern of care and impact of participation in clinical trials on outcome in ovarian cancer. Int J Gynecol Cancer 2005; in press
14. Koper NP, Kiemeney LALM, Massuger LFAG et al. Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in the Netherlands. Obstet Gynecol 1996; 88: 387-393
15. Beard CM, Hartmann LC, Atkinson EJ et al. The epidemiology of ovarian cancer: A population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol 2000; 10: 14-23
16. Ward LC, Fielding JWL, Dunn JA et al. The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. Br J Cancer 1992; 66: 943-950
17. Rahman ZU, Frye DK, Buzdar AU et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171-3177
18. Harter P, Schade-Brittinger C, Burges A et al. AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centres of the AGO Studiengruppe Ovarialkarzinom (abstr). J Cancer Res Clin Oncol 2004; 130 (Suppl): 130
19. McGowan L, Lesher LP, Norris HJ et al. Misstaging of ovarian cancer. Obstet Gynecol 1985; 65: 568-572
20. Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemo-Therapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003; 95: 113-125
21. Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997; 15: 3408-3415
22. Cress RD, O'Malley CD, Leiserowitz GS et al. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol 2003; 21: 1530-1535
23. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003; 21: 3488-3494
24. du Bois A, Pfisterer J, Meier W, Wagner U for the AGO Ovarian Cancer Study Group. Improving first-line therapy for advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective. Int J Gyn Cancer 2003; 13 (Suppl): 169-171
25. McNally OM, Delaney E, Petty RD et al. Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population based study. Br J Cancer 2003; 89: 966-967
26. Eisenkop SM, Spirtos NM. What are current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 2001; 82: 489-497